Several other research analysts have also issued reports on UCBJF. Jefferies Financial Group lowered UCB from a buy rating to a hold rating in a report on Monday, July 25th. Barclays decreased their target price on shares of UCB from €110.00 ($113.40) to €90.00 ($92.78) in a research report on Tuesday, June 7th. Berenberg Bank decreased their price objective on UCB from €120.00 ($123.71) to €111.00 ($114.43) and set a buy rating for the company in a report on Friday, July 15th. Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a $95.00 price target on shares of UCB in a research report on Friday, May 13th. Finally, Morgan Stanley reduced their target price on shares of UCB from €110.00 ($113.40) to €105.00 ($108.25) in a research note on Friday, July 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $105.25.
UCB Price Performance
UCBJF opened at $85.60 on Monday. The company has a fifty day moving average price of $88.62 and a two-hundred day moving average price of $102.14. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.25. UCB has a 1-year low of $85.60 and a 1-year high of $122.90.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
- Get a free copy of the StockNews.com research report on UCB (UCBJF)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.